GLP-1 maintenance dose protocols by drug 2026

Maintenance is the lowest dose that holds your loss: 2.4 mg on Wegovy, 5 to 15 mg on Zepbound, 0.5 to 2 mg on Ozempic. Three withdrawal trials measured the regain after people stopped, and the program you buy through moves the bill more than the dose does.

By John Samaras, EditorMay 27, 20264 min read

Maintenance is the lowest dose that holds your loss. That is 2.4 mg a week on Wegovy, 5, 10 or 15 mg on Zepbound, 0.5, 1 or 2 mg on Ozempic and up to 15 mg on Mounjaro. Most people reach it between week 16 and week 24. We read the four current FDA labels on Monday, August 17, 2026, and we reprice every program on this page every Monday. Nothing here is medical advice, and no dose change should happen without the person who wrote your prescription.

Some links here earn us a commission. Prices checked Monday, August 17, 2026.

Maintenance doses by drug

Drug (indication)Maintenance doseNotes
Wegovy (obesity)2.4 mg weekly, or 1.7 mg if 2.4 is not toleratedTitrated up over about 16 weeks. The June 2026 label allows a step to 7.2 mg for more weight loss. Below 1.7 mg is not supported. Also covers cardiovascular risk and MASH at 2.4 mg.
Zepbound (obesity, sleep apnea)5, 10 or 15 mg weeklyIndividualized, stepped up from a 2.5 mg start. Sleep apnea uses 10 or 15 mg. SURMOUNT-1 loss: 15.0% at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg.
Ozempic (type 2 diabetes)0.5, 1 or 2 mg weeklySet by A1C. The chronic kidney disease target is 1 mg. Not approved for obesity.
Mounjaro (type 2 diabetes)Up to 15 mg weekly2.5 mg steps, escalated on A1C. 10 mg maximum for ages 10 and up.

A patient at target on Zepbound 5 mg stays on 5 mg. The 7.2 mg ceiling comes from STEP UP, which measured 18.7 percent body weight loss at 72 weeks against 15.6 percent on 2.4 mg. That extra loss costs more side effects: gastrointestinal events ran 70.8 percent against 61.2 percent, and altered skin sensation 22.9 percent against 6.0 percent. The 7.2 mg pen also runs $50 a month more.

What happens when you stop

Three trials measured it. All found regain.

StudyDesignOn the drugOff the drug
STEP 4 (semaglutide 2.4 mg)803 adults randomized 2:1 at week 20 after titration, followed 48 weeks-7.9% further body weight+6.9% regained
SURMOUNT-4 (tirzepatide 10 or 15 mg)670 adults randomized 1:1 at week 36 after a 20.9% lead-in loss, followed 52 weeks-5.5% further body weight+14.0% regained
STEP 1 extension (semaglutide 2.4 mg)327 adults followed for a year after both the drug and the lifestyle program stopped at week 68n/a, everyone stoppedRegained 11.6 of 17.3 points lost

Among people who kept taking tirzepatide in SURMOUNT-4, 89.5 percent still held at least 80 percent of their lead-in loss at week 88. Among those switched to placebo, 16.6 percent did. The STEP 1 extension is the closest to real life, because everyone stopped: a year out, participants sat 5.6 percent below their start, having regained two-thirds of the loss. The likely driver is metabolic adaptation, the body defending the higher weight once appetite suppression ends.

What the loss looks like over time

STEP 1 reported a mean 14.9 percent loss at week 68, but behind that mean 50.5 percent of people lost at least 15 percent and 13.6 percent did not reach 5 percent. Loss is front-loaded. STEP 5 held semaglutide 2.4 mg to a 15.2 percent mean at week 104. SELECT, the longest randomized follow-up at 17,604 adults, measured 10.2 percent below baseline at week 208, four years in. Past four years there is no randomized evidence, so any five-year figure, including the cost totals below, is an extrapolation. The 2026 ADA Standards of Care treat obesity as a chronic disease needing ongoing therapy.

Muscle at maintenance

The SURMOUNT-1 DXA substudy scanned 160 people at 72 weeks. About 25 percent of the weight lost was lean tissue, and the placebo group that lost weight through diet lost the same proportion. Protein around 1.2 to 1.6 grams per kilogram of body weight and resistance training two or three times a week are associated with holding more lean tissue, though neither has been shown to prevent regain. Our protein calculator sets the gram target from your weight.

What the dose does to the bill

The program moves the five-year cost far more than the dose does. NovoCare sells the Wegovy injection at $349 a month at both 1.7 mg and 2.4 mg, cut from $499 in November 2025, and the 7.2 mg pen at $399. The Wegovy pill runs $149 at the 1.5 mg and 4 mg starter strengths (4 mg rises to $199 on September 1, 2026) and $299 at the 9 mg and 25 mg maintenance strengths. LillyDirect charges $299 at Zepbound 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and up, so a step down from 7.5 mg to 5 mg saves $50 a month. The Wegovy injection is $349 at both its doses, so the same step saves nothing there. The $449 Zepbound price holds only when your refill lands within 45 days. Miss that window and Lilly bills its regular $699 at 10 mg and above. For insured patients the copay tier is usually flat across doses.

22 programs with a verified all-in monthly price at the maintenance dose, checked Aug 24, 2026.

ProgramSupplyPer monthOne yearFive years
Strut HealthCompounded$149$1,788$8,940
ShedEither$159$1,908$9,540
FoundEither$169$2,028$10,140
Ivim HealthEither$175$2,100$10,500
Mochi HealthCompounded$178$2,096$10,680
Calibrate (plan copay)Branded$224$2,688$13,440
Noom MedEither$249$2,868$14,940
Lemonaid HealthCompounded$298$3,576$17,880
Amazon PharmacyBranded$299$3,588$17,940
KnownwellBranded$299$3,588$17,940
MedviCompounded$299$3,588$17,940
Sam's Club Member HealthBranded$299$3,588$17,940
Hone HealthCompounded$315$3,780$18,900
CVS MinuteClinicBranded$328$3,936$19,680
GoodRx for Weight LossBranded$338$4,056$20,280
Walgreens Weight ManagementBranded$348$4,176$20,880
Costco / Success by SesameBranded$358$4,296$21,480
Sesame CareEither$358$4,296$21,480
Ro BodyBranded$373$4,291$22,380
WeightWatchers ClinicBranded$373$3,432$22,380
Hims & HersBranded$448$5,116$26,880
LifeMDBranded$448$5,116$26,880

The spread from Strut Health to LifeMD is $17,940 over five years. 12 of these programs have changed price at least once in the 14 weekly snapshots taken since May 25, 2026. Compare all 22 on the chart.

Compounded semaglutide and tirzepatide come from a compounding pharmacy under a different regulatory route than an FDA-approved product, so the cheapest five-year total and the most expensive are not quotes for the same thing.

Cheapest to start is often not cheapest to stay

Introductory pricing is normal here. A reader who compares first months pays for it over five years, often for the same molecule, which is why the chart's headline price has been the maintenance price since June 2026.

The 6 programs whose introductory rate is not their maintenance rate, ranked by how far they fall. Rank is out of the 22 programs with a verified price, checked Aug 24, 2026.

ProgramFirst monthAt maintenanceRank on the first monthRank at maintenanceFirst year
WeightWatchers Clinic$25 for 3 months$3731 of 2220 of 22$3,432
Hims & Hers$188$4488 of 2221 of 22$5,116
LifeMD$188$4489 of 2222 of 22$5,116
Ro Body$188$37310 of 2219 of 22$4,291
Noom Med$129$2492 of 227 of 22$2,868
Mochi Health$138$1783 of 225 of 22$2,096

WeightWatchers Clinic ranks 1 of 22 on the first month at $25 and 20 of 22 once the introductory rate ends, at $22,380 over five years. Over the same five years, 16 programs that never discount a first month cost less.

Prices move

Maintenance is indefinite, and prices change. Every change we have recorded is at the price index.

How much does it cost to stay on a GLP-1 for five years?

It depends far more on the program than the dose, and on whether the drug is compounded or branded. Multiply a program's verified all-in monthly price by sixty for the five-year total at today's price.

Across the 22 programs on our chart with a verified all-in price, five years runs from $8,940 at Strut Health (compounded) to $26,880 at LifeMD (branded). Checked Aug 24, 2026.

Two situations can justify tapering off: planning a pregnancy, where the Wegovy label says to stop at least two months ahead because semaglutide has a long half-life, and a precipitating condition like type 2 diabetes that has resolved and no longer needs treatment. For weight management without one of those, the evidence supports staying on the lowest effective dose.

The program you buy through decides the five-year bill. See Mochi's flat all-in maintenance price and full score on the Mochi review page.

Sources

Evidence checked August 17, 2026

Each clinical claim above links to the document it came from, so you can read the source instead of trusting us. GLP Chart has no medical reviewer, and does not borrow a name for one. What that means.

  1. Wegovy maintenance dose, the 1.7 mg reduction, the 7.2 mg escalation and the MASH indicationFDA prescribing information for Wegovy, revised June 2026 (DailyMed)
  2. Zepbound titration, its 5, 10 and 15 mg maintenance doses and its two labeled indicationsFDA prescribing information for Zepbound, revised April 2026 (DailyMed)
  3. Ozempic maintenance doses and the chronic kidney disease targetFDA prescribing information for Ozempic, revised May 2026 (DailyMed)
  4. Mounjaro titration and its 15 mg adult maximumFDA prescribing information for Mounjaro, revised April 2026 (DailyMed)
  5. Continuing semaglutide against stopping it: -7.9% versus +6.9% over 48 weeksSTEP 4, Rubino et al., JAMA 2021;325:1414-1425
  6. Continuing tirzepatide against stopping it: -5.5% versus +14.0% over 52 weeks, and the 89.5% who held their lossSURMOUNT-4, Aronne et al., JAMA 2024;331:38-48
  7. One year after everything stopped: 11.6 of 17.3 percentage points regained, two-thirds of the lossSTEP 1 trial extension, Wilding et al., Diabetes Obes Metab 2022;24:1553-1564
  8. The one-year result of 14.9% and the spread of individual outcomes behind itSTEP 1, Wilding et al., N Engl J Med 2021;384:989-1002
  9. Two-year weight change on semaglutide 2.4 mg: -15.2% at week 104STEP 5, Garvey et al., Nature Medicine 2022;28:2083-2091
  10. Four-year weight change, the longest randomized follow-up: -10.2% at week 208SELECT weight analysis, Ryan et al., Nature Medicine 2024;30:2049-2057
  11. The tirzepatide dose-response curve at 5, 10 and 15 mgSURMOUNT-1, Jastreboff et al., N Engl J Med 2022;387:205-216
  12. About 25% of lost weight as lean tissue, the same share as the placebo armSURMOUNT-1 DXA body-composition substudy, Look et al., Diabetes Obes Metab 2025;27:2720-2729
  13. Semaglutide 7.2 mg against 2.4 mg, and what the higher dose costs in side effectsSTEP UP, Wharton et al., Lancet Diabetes Endocrinol 2025;13:949-963
  14. Obesity treated as a chronic disease requiring ongoing pharmacotherapyAmerican Diabetes Association, Standards of Care in Diabetes 2026, section 8
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.